1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Thymic epithelial tumor: new trials by email Literature Review of Thymic epithelial tumor trials Research Report on Thymic epithelial tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma Cyclophosphamide, Fludarabine, EB-CAR30-NK - B2 Thymoma, Thymic Carcinoma | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 36 | 2026-03-02 | 2026-05-20 |
Thymoma (1)
Hemic and Lymphatic Diseases (1) · Lymphatic Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Complex and Mixed (1) · Thoracic Neoplasms (1) · Thymus Neoplasms (1)
AP 1903 reagent (1) · Cyclophosphamide (1) · fludarabine (1)
Beijing Biotech (1)
China (1)